Alzheimer Disease, Battery
Conditions
Keywords
Alzheimer, Memantine, biomarkers, battery, cognition, imaging, neuropsychology
Brief summary
The early assessment of new drugs for Alzheimer's disease remains difficult because of the lack of predictive end-point. The use of a battery including different parameters could improve this early development of new drugs. Nevertheless, the interest of such a battery should previously be validated with the yet marketed AD drugs.
Detailed description
The aim of the present study is to test the effect of a 15-day treatment with memantine on a mixed battery associating cognitive assessment, imaging and neurophysiological tests in healthy volunteers. This multicenter, randomized, placebo-controlled, cross-over study is double-blind controlled and is conducted in 3 centers located in France (Lille, Marseille and Toulouse). 18-30 years old, healthy volunteers, without any neurological or psychiatric impairment, will complete 2 test sessions in a randomized order: one with a 15-day treatment with memantine, the other with placebo, and will be submitted to a mixed battery during the 14th and 15th day of the treatment. The primary outcome of the study will be based on cognitive assessment, imaging parameters and neurophysiological parameters
Interventions
DRUGMemantine
Memantine will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
DRUGPlacebo
the placebo will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
Sponsors
University Hospital, Lille
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 30 Years
Healthy volunteers
Yes
Inclusion criteria
* 18-30 year old male non-smoker subjects * Subject without cognitive impairment or cognitive complaint (Moca\>26, Mac Nair scale\<15) * Subject without history of brain disease (severe brain trauma, stroke, cerebral tumor,…) * Subject without major medical or surgical history * Subject without current chronic disease * Subject without current cerebral disease * Subject without vascular or metabolic risk factor * Subject without history or current mental disease or addiction (MINI) * Subject without lesion on MRI * Subject without abnormal electrical activities on EEG * Subject without use of chronic treatment or psychotropic drugs or substances * French speaker subject and able to understand the test instructions
Exclusion criteria
* Subject with dementia or cognitive decline identified by Moca \< 26 * Subject with vascular or metabolic risk factor * Subject with history or current mental disease or addiction * Subject with family history of young-onset dementia * Subject with family history of chronic or severe neurological or mental disease (first degree relatives) * Subject receiving a chronic treatment * Subject with claustrophobia or contra-indication to MRI * Subject unable to understand the test instructions
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacog battery | 15 days | * cognitive tests (8 items of the Cantab battery) : * Motor screening * 4 tests for visual memory (Delayed Matching to Sample, Paired Associated Learning, Pattern Recognition Memory, Spatial Recognition Memory) * 1 test for executive functions (Spatial Working Memory) * 2 tests for attention (Reaction Time, Rapid Visual Information Processing) * completed by a modified ADNI battery : ADAScog * imaging * fMRI * PET-FDG * neurophysiological * EEG |
Countries
France
Contacts
STUDY_CHAIRRégis Bordet, MD, PhD
University Hospital, Lille
Outcome results
None listed